BPC-157
Cytoprotective / Tissue RepairAlso known as: Body Protection Compound 157 · PL 14736 · Pentadecapeptide BPC 157
A stable gastric pentadecapeptide with broad regenerative & anti-inflammatory activity across musculoskeletal, gut, & neurological tissue.
Typical Dose
250–500 mcg/day
Route
Subcutaneous injection (near injury site or abdomen)
Cycle
4–12 weeks
Half-life
~4 hours (subcutaneous)
Storage
Lyophilized: room temp or freezer. Reconstituted: 2–8°C, use within 30 days.
Overview
BPC-157 is a synthetic 15-amino-acid peptide derived from a naturally occurring protein found in gastric juice. It has been studied extensively in preclinical models for its cytoprotective & regenerative properties, with effects spanning tendons, ligaments, muscle, bone, gut epithelium, & central nervous system tissue.
Its primary mechanism involves upregulation of growth hormone receptor expression in tendon fibroblasts, promotion of angiogenesis via VEGF & nitric oxide pathways, & modulation of dopaminergic & serotonergic neurotransmission. Unlike systemic growth factors, BPC-157 appears to act locally at sites of injury without driving systemic proliferation.
Human clinical data is limited. Most evidence comes from rodent models. Despite this, BPC-157 is widely used in performance & recovery contexts given its favorable tolerability profile & breadth of effect in preclinical literature.
Quick Start Guide
Reconstitute with bacteriostatic water (2 mL per 5 mg vial gives 2500 mcg/mL).
Draw 250 mcg (0.1 mL with the concentration above) into an insulin syringe.
Inject subcutaneously into the abdomen or near the site of injury, once or twice daily.
Run for 4 to 12 weeks depending on the indication. Most users report early signs of effect by week 2 to 3.
Research Indications
Tendon & ligament healing
Most EffectiveMultiple rodent studies show accelerated collagen remodeling & return of tensile strength in Achilles tendon transection models. The mechanism involves upregulation of GH receptors in tendon fibroblasts & promotion of tendon-to-bone reattachment.
Gastrointestinal repair
Most EffectiveDerived from gastric juice, BPC-157 shows dose-dependent protection against ethanol-, NSAID-, & stress-induced gastric lesions in rodents. Also studied in inflammatory bowel disease models with consistent epithelial repair effects.
Muscle & wound healing
EffectiveAccelerates healing of full-thickness skin wounds, surgical incisions, & crush injuries in rat models. Promotes angiogenesis & fibroblast activity at the wound site.
Anti-inflammatory (systemic)
EffectiveReduces markers of systemic inflammation in sepsis & organ failure models. Proposed mechanism involves nitric oxide pathway modulation.
Bone healing & osteoporosis
ModerateStudies in rodents show increased bone density & faster fracture healing, particularly in combination with TB-500.
CNS neuroprotection
ModerateRodent studies show protective effects against dopaminergic neurotoxicity, spinal cord injury, & traumatic brain injury. Mechanism is unclear but may involve nitric oxide & neurotrophic signaling.
Erectile dysfunction (NO pathway)
Research OnlyAnimal studies show improved erectile function via penile smooth muscle relaxation through nitric oxide modulation. No human data.
Research Protocols
General soft tissue recovery
4–8 weeksDose
250 mcg
Frequency
Twice daily
Route
SubQ near injury site
Intensive injury (tendon/ligament tear)
8–12 weeksDose
500 mcg
Frequency
Once daily
Route
SubQ or IM near injury
Some protocols split 500 mcg into two 250 mcg injections AM/PM.
Gastrointestinal healing
4–8 weeksDose
250 mcg
Frequency
Twice daily
Route
SubQ abdomen or oral (dissolved in water)
Oral route is used specifically for upper GI conditions. SubQ is preferred for systemic or lower GI effects.
Maintenance / prevention
Ongoing (cycled 8 on / 4 off)Dose
125–250 mcg
Frequency
Once daily
Route
SubQ abdomen
Localized joint protocol
4–6 weeksDose
250 mcg
Frequency
Once daily
Route
Inject within 1–2 cm of affected joint
Do not inject directly into the joint capsule. Periarticular SubQ is standard.
Peptide Interactions
The canonical Wolverine Stack. BPC-157 works locally at the injury site through GH receptor upregulation; TB-500 acts systemically via actin regulation & cell migration. Together they address both the local repair cascade & systemic tissue remodeling. Commonly run together at standard doses of each.
Adding a GH secretagogue amplifies downstream IGF-1, which complements BPC-157's local repair signaling. A common recovery stack, especially post-surgery.
Frequently stacked with Ipamorelin for GH pulse amplification alongside BPC-157. No known adverse interaction.
Occasionally used together; different mechanisms (NO vs. melanocortin). No known interaction.
Side Effects & Safety
Common
- Injection site redness or mild swelling (resolves within hours)
- Transient fatigue after injection
- Vivid dreams (reported anecdotally, mechanism unknown)
Uncommon
- Nausea (rare, more common with oral administration)
- Mild headache
- Lightheadedness shortly after injection
When to Stop
- Signs of allergic reaction: hives, difficulty breathing, swelling of face or throat
- Persistent pain or abscess at injection site
- Unexplained rapid heart rate or chest discomfort
- Known or suspected malignancy (growth-promoting peptides are generally avoided)
How to Reconstitute
Clean the vial stopper with an alcohol swab & allow to dry for 30 seconds.
Draw 2 mL of bacteriostatic water (BAC water) into a 3 mL syringe.
Tilt the BPC-157 vial at 45° & slowly inject the BAC water down the inner wall of the vial. Do not spray directly onto the powder.
Gently swirl the vial for 20–30 seconds until the powder is fully dissolved. Do not shake.
The resulting solution should be clear & colorless. Label the vial with the date.
Transfer to the refrigerator (2–8°C). Use within 30 days.
For each 250 mcg dose: draw 0.1 mL into an insulin syringe (with this 2 mL / 5 mg reconstitution giving 2500 mcg/mL).
Dosing math: Standard dilution is 2 mL BAC water per 5 mg vial, yielding 2500 mcg/mL (0.1 mL = 250 mcg). For 500 mcg doses, draw 0.2 mL.
Quality Indicators
Good — use as normal
- Crystal clear, colorless solution after reconstitution
- Powder dissolves fully within 60 seconds of gentle swirling
- Lyophilized cake appears white & solid, not yellowed or powdery
Acceptable
- Minor clumping that dissolves with continued gentle swirling
- Faint yellowish tint in lyophilized form (oxidation at trace level; within spec for most reputable manufacturers)
Discard immediately
- Cloudy or particulate solution after reconstitution
- Visible precipitate that does not dissolve
- Discoloration (brown, orange) after reconstitution
- Powder appears gel-like or has fused to the side of the vial
- Stored reconstituted at room temperature for more than 48 hours
What to Expect
Week 1–2
Minimal subjective changes for most users. Some report reduced pain at the injury site by day 7–10. The anti-inflammatory effect is measurable before structural repair is underway. Sleep quality improvements are sometimes noted early.
Week 3–4
The most commonly reported window for first subjective improvements in mobility & pain reduction. Fibroblast activity & collagen synthesis are increasing but the new tissue is not yet mechanically mature.
Week 5–8
Continued improvement in functional range of motion, especially with tendon & ligament protocols. GI users often report significant symptom improvement by week 6. Cumulative angiogenesis is now contributing to tissue perfusion.
Week 9–12
Final maturation of repaired tissue. Many users complete their cycle here. Gains in tensile strength & functional output continue but at a slower rate. Some maintain on a lower dose (125 mcg/day) after this phase.
Post-cycle
Effects are generally durable. Structural repair that has occurred does not reverse on discontinuation. Re-injury risk may be elevated if training volume is increased too quickly post-cycle before full tissue maturation.
Community Insights
Self-reported. Reflects user experience, not clinical outcomes.
Research References
Current Pharmaceutical Design · 2011
Reviews clinical development of BPC-157 for IBD. Discusses the cytoprotective mechanism & the transition from animal to early human data.
doi:10.2174/138161211798764903 →Life Sciences · 2014
Demonstrates BPC-157's cardioprotective properties in the context of antipsychotic-induced arrhythmia, suggesting a modulatory role in cardiac electrical activity.
doi:10.1016/j.lfs.2014.09.029 →Current Pharmaceutical Design · 2018
Comprehensive review of BPC-157's angiogenic mechanism including VEGF pathway upregulation & NO synthase modulation. Central to understanding its wound healing efficacy.
doi:10.2174/1381612824666180430091528 →Biomedicines · 2021
Rodent study showing histologically confirmed accelerated tendon-to-bone reattachment with BPC-157 treatment, with quantified tensile strength improvement over controls.
doi:10.3390/biomedicines9070781 →Verify what you have
Information on this page applies to pharmaceutical-grade peptides. Purity & identity of research-grade products vary. Certipep provides independent ESI-TOF-MS & HPLC analysis with a signed analytical report.
Submit a sample